ApTOLL
Acute Ischemic Stroke
Phase 2Transferred
Key Facts
About aptaTargets
aptaTargets is a Spanish biotechnology company specializing in aptamer-based therapeutics for acute inflammatory conditions. Its lead asset, ApTOLL, a TLR4-targeting aptamer for acute ischemic stroke, has completed a positive Phase 1b/2a trial and received EMA PRIME designation. Following a strategic transfer of ApTOLL to Merck in 2024, aptaTargets is positioned to potentially advance its platform into other acute indications like myocardial infarction and multiple sclerosis.
View full company profileTherapeutic Areas
Other Acute Ischemic Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| Presendin™ (Exenatide) | Invex Therapeutics | Phase 2 |
| Supernova Stent Retriever | Gravity Medical Technology | Commercial |
| Neutron Reperfusion Catheter | Gravity Medical Technology | Commercial |
| AST-004 | Astrocyte Pharmaceuticals | Phase 1/2 |
| scp776 | Silver Creek Pharmaceuticals | Phase 2 |
| VB-001 | VST Bio | Pre-clinical |
| Pulse NanoMED for AIS | Euphrates Vascular | Pre-clinical |
| NeVa NET | Vesalio | Development/Commercial |
| ThermoSuit® for Acute Ischemic Stroke | Life Recovery Systems HD | Pivotal Trial (Planned) |
| Pulsante for Ischemic Stroke | Realeve | Research/Clinical Study |
| Glenzocimab (ACT017) | Acticor Biotech | Phase 2/3 |
| eTrieve™ Microcatheter | Magneto Thrombectomy Solutions | Phase 1 |